IDEXX insider activity: Emerson acquires 1,849 shares; 402 sold

Rhea-AI Filing Summary

Andrew Emerson, EVP, CFO and Treasurer of IDEXX Laboratories (IDXX), reported insider transactions dated 08/07/2025. The filing shows an acquisition of 1,849 common shares at $141.60 and a disposition of 402 common shares at $650.06. Following the reported transactions, beneficial ownership is shown as 4,272.778 shares (direct) after the acquisition and 3,870.778 shares (direct) after the disposition. The filing notes 27.3420 shares purchased under the employee stock purchase plan on March 31, 2025 and June 30, 2025, and references a grant of an option to buy 1,849 shares that vested on February 14, 2022. The form is signed by an attorney-in-fact on 08/11/2025.

Insights

Financial Analyst

TL;DR: Insider acquired 1,849 shares at $141.60 and sold 402 shares at $650.06 on 08/07/2025; holdings updated.

The Form 4 discloses a simultaneous acquisition and disposition by Andrew Emerson, IDEXX's EVP/CFO. The acquisition amount is 1,849 shares at $141.60 and the disposition is 402 shares at $650.06. Beneficial ownership counts are reported as 4,272.778 shares (after acquisition) and 3,870.778 shares (after disposition), both held directly. The filing also documents 27.3420 ESPP shares purchased earlier in 2025 and references a previously vested option for 1,849 shares. This filing records routine officer transactions and updates holdings; it does not itself provide operational or financial guidance.

Corporate Governance Expert

TL;DR: Form 4 shows routine reporting of option-related activity, ESPP purchases and a sale; form is signed by attorney-in-fact.

The document identifies Andrew Emerson as the reporting person and states his relationship to the issuer as EVP, CFO and Treasurer. Explanatory notes explicitly state 27.3420 ESPP shares purchased on March 31 and June 30, 2025 and a grant of an option to buy 1,849 shares that vested on February 14, 2022. The filing bears an attorney-in-fact signature dated 08/11/2025, indicating execution on the reporting person's behalf. The disclosure appears consistent with routine Section 16 reporting requirements and provides required transaction details and ownership totals.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Emerson Andrew

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK ME 04092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CFO and Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2025		M		1,849	A	$141.6	4,272.778(1)	D
Common Stock	08/07/2025		F		402	D	$650.06	3,870.778	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right-to-buy)	$141.6	08/07/2025		M			1,849	(2)	02/13/2027	Common Stock	1,849	(3)	0	D

Explanation of Responses:

1. Includes a total of 27.3420 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025.

2. Grant of option to buy 1,849 shares of Issuer common stock that vested on February 14, 2022.

3. Not applicable.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Andrew Emerson	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Andrew Emerson (IDXX) report on Form 4?

The Form 4 reports an acquisition of 1,849 common shares at $141.60 and a disposition of 402 common shares at $650.06, both dated 08/07/2025.

How many shares did Emerson beneficially own after the reported transactions?

The filing shows beneficial ownership of 4,272.778 shares (direct) after the acquisition and 3,870.778 shares (direct) after the disposition.

Were any employee stock purchase plan (ESPP) purchases disclosed?

Yes. The filing states inclusion of 27.3420 shares purchased under the ESPP on March 31, 2025 and June 30, 2025.

Does the filing reference any options or grants for Emerson?

Yes. The filing references a grant of an option to buy 1,849 shares that vested on February 14, 2022.

When was the Form 4 signed and by whom?

The form is signed by Lily J. Lu, Attorney-in-Fact for Andrew Emerson on 08/11/2025.